Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
08:15am, Thursday, 09'th Jul 2026
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
12:15pm, Tuesday, 07'th Jul 2026
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Buy these quality, low-stress stocks for the summer, says Jefferies
11:45am, Tuesday, 07'th Jul 2026
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more th
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
10:45am, Tuesday, 07'th Jul 2026
AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.
3 Dividend Aristocrats to Buy in July
08:00am, Tuesday, 07'th Jul 2026
Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026.
The Dividend ETF Quietly Outperforming the S&P 500
05:30am, Tuesday, 07'th Jul 2026
This dividend ETF's focus beyond yield continues to pay off for investors.
TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2 ) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in th
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
11:51am, Monday, 06'th Jul 2026
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.
04:22pm, Friday, 03'rd Jul 2026
The average Social Security retirement check reached $2,081 per month as of April 2026, according to the Social Security Administration's monthly statistical data. That figure carries the 2.8% cost-of
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
08:37am, Friday, 03'rd Jul 2026
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
10:00am, Thursday, 02'nd Jul 2026
JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.
3 Dividend Stocks to Buy Hand Over Fist in July
08:00am, Thursday, 02'nd Jul 2026
Dividend investors entering July 2026 have a rare setup: Three of the market's most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 mo
AbbVie: Apogee Deal Just Widened An Already Dominant Moat
12:47am, Thursday, 02'nd Jul 2026
AbbVie is acquiring Apogee Therapeutics for $10.9B, reinforcing its immunology franchise and addressing future patent cliffs proactively. Skyrizi and Rinvoq have already replaced Humira's revenue, wit
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
03:45pm, Tuesday, 30'th Jun 2026
AbbVie knows how to plan ahead.
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
01:35pm, Tuesday, 30'th Jun 2026
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
